Health

Pure Science vs. Biopure

Biopure, a company that makes blood substitutes, is suing scientist Charles Natanson for defamation after he published a critical review in the Journal of the American Medical Association. Nature magazine has condemned the lawsuit.

Health Hype About Statins

  • Topics: Health
  • Voices of caution are responding to recent breathless headlines about the supposed heart-health benefits of statin drugs. Publications including Fox News, the Wall Street Journal and the New York Times claimed "that millions more people could benefit from taking the cholesterol-lowering drugs known as statins." As health reporter Andre Picard points out, the net health benefits from statins are actually "modest."

    The headlines were based on a study published in the New England Journal of Medicine. However, the study failed to impress Merrill Goozner of the Integrity in Science Project at the Center for Science in the Public Interest. Goozner reviewed the study closely and found it interesting mostly for "what it reveals about profit-driven medical research and how it contributes to making the U.S. health care system the most bloated and wasteful in the world."

    Obama 2.0

    The election of Barack Obama as America's next president has prompted a number of analyses of what has been described as "one of the most effective presidential campaigns that's ever been run." Now the Obama team is showing that it intends to use some of the same new internet technologies that made it "

    Master Settlement Agreement, or a Masterful Status-quo Agreement?

  • Topics: Health, Tobacco
  • November 23, 2008 marks ten years since 46 state Attorneys General and the major American tobacco companies signed the big tobacco Master Settlement Agreement (MSA). Besides being the largest legal settlement in history and resolving an unprecedented onslaught of litigation against the industry, the MSA required tobacco companies to pay approximately $200 billion to the states over 25 years (subject to tweaks for inflation and market share).

    The devil, however, was in the details. Heralded at the time as a defeat for the tobacco industry and a victory for public health, the MSA has actually done little to change the status quo. It ended some forms of tobacco advertising, for example, but the restrictions adopted were in reality less important to the industry than to public health authorities. The industry abandoned billboards and transit ads, ads in magazines with a high youth readership, and ads within a certain distance of schools. However, it continued marketing through high levels of advertising, bar nights, event sponsorships, direct mail, and retail placements.

    A Drink to Your Health (Unless We Also Sell the Sugary Stuff)

    "Bottled water sales in the past have grown mainly from consumers moving to water from soda and other sugary beverages," fueled by rising childhood and adult obesity rates. But ads for bottled water don't push the health angle, because many bottled water companies also sell soda.

    The Media Buries the Message: Tobacco Prevention vs. High-Cost Drugs

    Cholesterol-reducing drugs called statins have been in the news lately following the release of a major medical study that found that statins can prevent heart disease and stroke in people with no previous history of heart disease.

    Statins are among the biggest-selling family of drugs of all time. Many articles about the study mentioned above, including one on the credible web site WebMD, also mention the specific drug used in the study: Crestor.

    The study has generated hundreds of articles, most of which repeat the same basic framing of the issue: if heart disease is the problem, a drug is the answer.

    Bisphenol A: A Chemical with Deep-Pocketed Friends

    The same month that Martin Philbert was named the chair of a U.S. Food and Drug Administration (FDA) panel considering the safety of bisphenol A, a defender of the chemical made a $5 million grant to Philbert's research center.

    Pfizer Turns Failure into Success

    "Documents and emails released this week ... suggest Pfizer's marketers influenced" research on the drug Neurontin "by declining to release or altering the conclusions of studies that found no beneficial effect from Neurontin for various off-label conditions," reports Keith Winstein.

    Supreme Court to Hear Case About Low Tar/Low Nicotine Fraud

    The U.S. Supreme Court opened its 2008-2009 session today by hearing a case about whether cigarette makers have defrauded smokers with implied claims about the relative safety of "light" and "low tar" cigarettes. At issue is the question of preemption, a legal doctrine that holds that federal laws can take precedence over some state laws. The tobacco companies are arguing that they should not be held responsible for labeling and advertising that was approved by the Federal Trade Commission (FTC). The FTC, which has long required that cigarette packs be labeled as to how much "tar" and nicotine they deliver, argues that the agency itself was fooled because tobacco companies hid internal research data that showed smokers did not benefit from switching to light or low tar cigarettes. In August 2006, U.S. District Court Judge Gladys Kessler, in the landmark U.S. Department of Justice case against the industry, ruled that cigarette makers purposely misled smokers into believing that light cigarettes were more safe than regular cigarettes, and now more than 30 class action lawsuits on the issue of the tobacco industry's "light" and "low tar" cigarette fraud are currently pending across the U.S. The Supreme Court's ruling in this case could either affirm or invalidate all of them.

    Not Following the Pharma Money

    Medical research conflicts of interest are in the news lately, thanks to recent congressional hearings by Senator Charles Grassley. But are journalists part of the problem?

    Syndicate content